Slamon et al. observed that a non-anthracycline trastuzumab-based regimen in HER-2–positive breast cancer patients not only showed an efficacy similar to anthracycline concurrent with trastuzumab, but also resulted in fewer acute toxic effects, including lower risks of cardiotoxicity and leukemia [47]. The gene discussed is ERBB2; the disease is breast carcinoma.